Clinical trial · Observational
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
NCT01464216CI-TRIAL-00059172FuncProstactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal being predicting of prostate cancer aggressiveness.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Genital Neoplasms, Male | — | UNRESOLVED | — |
| Prostatic Diseases | — | UNRESOLVED | — |
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Death
- timeFrame
- 2030
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Patients suitable for surgery with confirmed prostate cancer, Gleason grade ≥ 3 * Patient has received no prior treatment for prostate cancer. * Patient has adequate renal function: Estimated creatinine clearance ≥ 60 ml/minute. * Patient must sign written informed consent according to the protocol approved by the Regional Ethics Committee. Exclusion Criteria: * Patient with contraindication to MR or MR contrast media according to clinical practice. * Patients who want to withdraw for any reason during the study. * Patients previously undergone pelvic surgery or radiation therapy
References
Publications (0)
Data not yet available
No reference posted for this study.